Core Insights - Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology R&D platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. focuses on circRNA technology platform development and innovative drug development, also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] Group 2: Collaboration Focus Areas - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Baijin's exosome and cell platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, cerebral infarction, Alzheimer's, and Parkinson's diseases [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

Group 1 - Company Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity acquisition, aiming to establish a leading global circRNA technology research and development platform [1] - The agreement is set to expire on December 31, 2026, and either party can terminate the agreement with a 10-day notice [1] Group 2 - Youhuan is a biopharmaceutical company focused on circRNA technology platform development and innovative drug development, also providing CRO services [2] - Youhuan has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] - The company is engaged in deep cooperation with large enterprises in the international drug development field and has signed contracts in certain cell application areas with a global multinational company [2] Group 3 - The initial focus of the collaboration will include exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Research will also target circRNA and exosome drug delivery technologies, developing new delivery systems based on exosome and cell platforms [3] - The development of engineered exosome drugs and cell drugs for cardiovascular and tissue repair applications, as well as treatments for neurodegenerative diseases like Alzheimer's and Parkinson's, is also a priority [3] - The collaboration aims to develop precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

Core Insights - Baijin Life Sciences (01466.HK) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology research platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan is a dual-driven biopharmaceutical company focusing on circRNA technology platform research and innovative drug development, while also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for its proprietary "Circular RNAs and Preparation Methods" and a Chinese invention patent for a method based on ribozyme self-splicing [2] Group 2: Collaboration Focus - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Youhuan's platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, stroke, and neurodegenerative diseases like Alzheimer's and Parkinson's [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]